Data as-of 2026-07-17 close.

ISRG had the worst single session in this entire read: -14.15% in one day on nearly 4x average volume, landing at RSI 30.2 and -42.8% off its 52-week high — a name the July 11 scan flagged as "recovery stalled and reversed" just broke outright. ZTS is still the sector's most structurally broken name, -52.3% from its high, though it ticked up modestly this week. Everything else in the group is quieter: UNH, CVS, GH, and DXCM are all climbing on steady 3-month gains, and this cut reads the same 21-name healthcare.json universe as last scan — no composition change.

Source: healthcare.json (the broader 21-name universe, not the narrower healthcare-scan.json cut). Latest bar 2026-07-17 for every name in this cut. Prior scan: 2026-07-11-healthcare-scan.

The dominant story in today's healthcare read is ISRG's collapse. The stock dropped 14.15% in one session on 3.89x its average volume (1-day change and relative volume per healthcare.json), pushing RSI down to 30.2 and the price -42.8% below its 52-week high. This is the same move showing up in this session's biotech-scan cut — ISRG sits on both watchlists — and the underlying regime classifier now reads "collapse" here too, even though the thesis flag is still marked "intact."

ZTS remains the sector's other clearly broken name. RSI ticked up slightly to 46.9 from 42.2 eleven days ago, but the stock is still -52.29% from its 52-week high and in a "collapse" regime, with the 3-month change now -37.61% — worse than the -36.8% flagged last scan. This is the same collapse thesis flagged as "still live" on July 11.

MRNA kept sliding this week, RSI 54.8 → 45.9, -9.45% over the past week, though it's still up 13.24% over 3 months. Away from those three names, the rest of the sector is comparatively quiet: CVS (RSI 68.5), UNH (58.4), and GH (56.9) are all posting strong 3-month gains (CVS +41.58%, UNH +32.47%, GH +71.15%) without screening as overbought, and ABT had the sector's best single week, +7.96%.

• ISRG broke. RSI 45.0 (07-11) → 30.2 today, a -14.15% single-session drop on 3.89x average volume — the regime now reads "collapse" rather than "pullback." Thesis flag still reads "intact."
• ZTS improved only modestly and remains broken. RSI 42.2 → 46.9, +1.32% over the past week, but 3-month change worsened to -37.61% from -36.8% — still -52.3% from its 52-week high, strong-down DC.
• MRNA kept declining. RSI 54.8 → 45.9, -9.45% over the past week (change7d).
• VRTX roughly held its ground. RSI 53.1 → 53.4, essentially flat.
• PFE improved meaningfully. RSI 41.5 → 53.6, +3.64% over the past week — the sector's weakest large-cap last scan is no longer the weakest.
• ABT had the sector's best week. +7.96% (change7d), RSI climbing to 67.2.
• GH cooled from its parabolic 3-month run but remains extended: RSI 63.4 → 56.9, still +71.15% over 3 months.
• AMGN, GILD, TMO remain steady — all still RSI 57-62 with uptrends intact, none extended.
• Universe unchanged. Same 21 tickers as the July 11 healthcare.json cut — no composition change, no entrants or dropouts.

RSI measures how stretched a stock is over the past 14 sessions — under 30 is oversold, over 70 is overbought/extended. vs SMA20 is the price gap to the 20-day average. vs VWAP is the premium over the average price paid by current holders — a useful gut check on how much of a move is unrealized gain that could get sold into weakness. Trend combines direction/strength with a cross signal: GC (golden cross) is structurally healthier than DC (death cross). A stock at a low RSI while the regime classifier reads "collapse" — like ISRG here — means the price move hasn't been confirmed by the underlying structure; treat it as "watch," not "buy."

None.

None. ISRG at 30.2 is the sole name near this band but doesn't clear the 30 threshold on the downside — still the sector's lone real trouble spot after its single-day break.

• Weak / unresolved (RSI 40-50): MRNA, ZTS. ZTS is the standout for how broken it is (-52.3% from ATH, strong-down DC, "collapse" regime) — the collapse thesis flagged last cycle is confirmed still live.
• Basing / cleanest accumulate (RSI 50-59): SYK, BIIB, VRTX, PFE, JNJ, LLY, MDT, GILD, GH, AMGN, MRK, UNH, DXCM. AMGN, GILD, and TMO (just above, at 62.3) remain the standout steady names — never got extended.
• Continuing / momentum (RSI 60+): TMO, VEEV, HROW, ABT, CVS. CVS is the sector's most extended survivor at RSI 68.5, still not overbought by the 70 threshold.

• ISRG's single-day break is the same move showing up in this session's biotech read — is there a real catalyst behind it, or is this a broader medtech/robotics read-through worth tracking as one name across both cuts?
• ZTS remains deeply broken (-52.3% from ATH) despite a modest RSI tick-up — is the collapse thesis still live, or does this week's small bounce mark the start of a floor?
• PFE just had its best week in a while — does it confirm into a real reversal next scan, or was this a one-week move?
• GH and VEEV both carry big 3-month gains (+71.2% and +27.5%) without extreme RSI readings — does either name's structure confirm the move with a golden cross, or does it stay unconfirmed?

• Tape data (price/RSI/SMA/returns): full-scan pre-computed summaries as of the 2026-07-17 close — *.